Duticin

Duticin

dacarbazine

Manufacturer:

Korea United Pharma

Distributor:

Qualimed
Concise Prescribing Info
Contents
Dacarbazine
Indications/Uses
Metastatic malignant melanoma, Hodgkin's disease, neuroblastoma, soft tissue sarcoma including leiomyosarcoma.
Dosage/Direction for Use
2-4.5 mg/kg/day IV for 10 days repeated at intervals of 4 wk or 250 mg/m2 daily for 5 days, repeated at intervals of 3 wk. Malignant melanoma 850 mg/m2 IV infusion at 3 wk interval. Hodgkin's disease 150 mg/m2/day for 5 days in combination w/ other effective drugs. May be repeated every 4 wk or 375 mg/m2/day in combination w/ other antineoplastic agents, to be repeated every 15 days.
Contraindications
Special Precautions
Hepatic or renal impairment, complicated infections, chickenpox. Monitor blood, hepatic & renal functions. Long-term therapy. Bleeding tendency. Women of childbearing potential. Lactation. Childn.
Adverse Reactions
Pancytopenia, anemia, leukopenia, thrombocytopenia; increased GOT, alkaline phosphatase, LDH, total bilirubin level, decreased serum total protein; increased BUN, proteinuria; anaphylaxis, photosensitivity, nausea, vomiting, anorexia, diarrhea, gastralgia; giddiness, mouth numbness, facial paresthesia, erythematous eruption, urticaria, alopecia; vascular pain; malaise, myalgia, headache, ruber, flush, flu-like syndrome.
Drug Interactions
Concomitant use w/ other anti-neoplastic drugs or radiotherapeutics.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01AX04 - dacarbazine ; Belongs to the class of other alkylating agents. Used in the treatment of cancer.
Presentation/Packing
Form
Duticin inj 200 mg
Packing/Price
(Vial) 10 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in